PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
PharmaTher Expands PharmaPatch Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
PharmaTher Applauds FDA's Commissioner's National Priority Voucher Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505 Focus, and Upside from Strategic ANDA Sale
PharmaTher Announces KetAImine - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505 NDA Filings
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine ), Aligned with FDA's CNPV National Priority Initiative
Pinnacle Hires San Diego Torrey Hills Capital for Investor Relations and Grants Incentive Stock Options
SAGA Metals Achieves 100% Drilling Success in 2025-Reports Final Assays from Trapper South at Radar Critical Minerals Project in Labrador
